Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Apr 7;55(3):163–170. doi: 10.4132/jptm.2021.02.22

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2021 The Korean Society of Pathologists/The Korean Society for Cytopathology

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1 — Representative pictures for the comparison of programmed death-ligand 1 (PD-L1) assays and differences in scoring algorithm of urothelial carcinoma (UC). (A) Scoring algorithm of SP142 is based on the proportion of tumor area that is occupied by PD-L1-expressed immune cells (ICs) at any intensity. (B) Scoring algorithm of 22C3 is determined by using the combined positive score (CPS) in UC, which is the number of PD-L1–stained cells (tumor cell [TC] plus IC) divided by the total number of viable TCs, multiplied by 100. (C) SP263 status is determined by the percentage of TCs obtained by performing any membrane staining or by the percentage of tumor-associated ICs obtained by staining at any intensity. SP263-expressed TC area proportion of the tumor area is determined. Also, the percentage of tumor area occupied by any tumor-associated IC (Immune Cells Present, ICP) is used to determine IC expression, and IC positivity is defined as the percentage of PD-L1–positive IC area in ICP.